Phosphoflow-Based Evaluation of Mek Inhibitors as Small-Molecule Therapeutics for B-Cell Precursor Acute Lymphoblastic Leukemia

Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia

(2015) Seyedmehdi Shojaee et al.   CANCER CELL

Self-Enforcing Feedback Activation between BCL6 and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia

(2015) Huimin Geng et al.   CANCER CELL

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health

(2015) William H. Chappell et al.   Oncotarget

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades

(2015) James Andrew McCubrey et al.   Oncotarget

Simultaneous targeting of PI3Kδ and a PI3Kδ-dependent MEK1/2-Erk1/2 pathway for therapy in pediatric B-cell acute lymphoblastic leukemia

(2015) Xiang Wang et al.   Oncotarget

Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition

(2014) J. Irving et al.   BLOOD

Phospho-flow detection of constitutive and cytokine-induced pSTAT3/5, pAKT and pERK expression highlights novel prognostic biomarkers for patients with multiple myeloma

(2014) R Brown et al.   LEUKEMIA

Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy

(2013) Y.-T. Hsieh et al.   BLOOD

FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: a Children's Oncology Group report

(2012) M. S. Redell et al.   BLOOD

Single-Cell Pharmacodynamic Monitoring of S6 Ribosomal Protein Phosphorylation in AML Blasts during a Clinical Trial Combining the mTOR Inhibitor Sirolimus and Intensive Chemotherapy

(2011) A. E. Perl et al.   CLINICAL CANCER RESEARCH

BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR–ABL1 kinase inhibition

(2011) Cihangir Duy et al.   NATURE

PI3K/p110  is a novel therapeutic target in multiple myeloma

(2010) H. Ikeda et al.   BLOOD

A Functional Receptor for B-Cell–Activating Factor Is Expressed on Human Acute Lymphoblastic Leukemias

(2010) Reshmi Parameswaran et al.   CANCER RESEARCH

Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia

(2010) F Fei et al.   LEUKEMIA

Activity of the Aurora Kinase Inhibitor VX-680 against Bcr/Abl-Positive Acute Lymphoblastic Leukemias

(2010) F. Fei et al.   MOLECULAR CANCER THERAPEUTICS

Mutation of Genes Affecting the RAS Pathway Is Common in Childhood Acute Lymphoblastic Leukemia

(2008) M. Case et al.   CANCER RESEARCH